Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03711-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Gaoqi Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. Hauptthemen laut MEDLINE: Mitoxantrone, Liposomes, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study is aimed at investigating the pharmacokinetic (PK) characteristics of pegylated liposomal mitoxantrone (PLM) in patients with relapsed/refractory lymphoma or small cell lung cancer (SCLC) by constructing population pharmacokinetic (popPK) models for both liposome-encapsulated mitoxantrone and free mitoxantrone. METHODS: A total of 23 patients with relapsed/refractory lymphoma and 42 patients with SCLC were included. A popPK model was simultaneously developed utilizing a non-linear mixed effects model (NONMEM) to explore the PK profiles of liposome-encapsulated mitoxantrone and free mitoxantrone. Clearance (CL) and distribution volume (V) were calculated, and covariate analysis was employed to evaluate the influence of patient disease type, demographic information, and biochemical indicators of liver and kidney function on PK parameters. RESULTS: The concentration-time profiles for both liposome-encapsulated mitoxantrone and free mitoxantrone were described by a one-compartment model. The release (Rel) of liposome-encapsulated mitoxantrone to free mitoxantrone was determined to be 0.0191 L/h, and the V of liposome-encapsulated mitoxantrone was 2.32 L. The apparent CL of free mitoxantrone was estimated at 1.66 L/h. The apparent V of free mitoxantrone was 35.8 L in patients with relapsed/refractory lymphoma and 22.2 L for patients with SCLC. In patients with relapsed/refractory lymphoma, lower maximum concentration (Cmax) and higher apparent V of free mitoxantrone were observed compared with patients with SCLC. CONCLUSION: The popPK characteristics of both liposome-encapsulated and free mitoxantrone in patients with relapsed/refractory lymphoma or SCLC were effectively described by a one-compartment model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang, Hebei, 050035, China.
- CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang, Hebei, 050035, China. lchunlei@cspc.cn.
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. wangjq@zjcc.org.cn.
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. fangluo@zjcc.org.cn.
Zitieren
APA
Xu, G., Yang, D., Ding, H., Zhong, L., Zhu, J., Mi, X., Zhang, X., Wu, Z., Xin, W., Li, C., Wang, J., & Fang, L. (2024). Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03711-8
Vancouver
Xu G, Yang D, Ding H, Zhong L, Zhu J, Mi X, et al. Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03711-8
BibTeX
@article{Xu2024,
author = {Xu, Gaoqi and Yang, Dihong and Ding, Haiying and Zhong, Like and Zhu, Junfeng and Mi, Xiufang and Zhang, Xueyuan and Wu, Zhufeng and Xin, Wenxiu and Li, Chunlei and Wang, Jiaqi and Fang, Luo},
title = {Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03711-8}
}
EUVIMED